☆ 4.7 Article

Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

Patient-Derived Primary Cancer-Associated Fibroblasts Mediate Resistance to Anti-Angiogenic Drug in Ovarian Cancers

Raed Sulaiman et al.

Summary: Ovarian cancer is highly aggressive and often has a poor prognosis due to late-stage diagnosis and resistance to anti-angiogenic therapy. The tumor microenvironment, including immune cells, cancer-associated fibroblasts, and endothelial cells, plays a critical role in promoting metastasis and drug resistance. This study investigated the interaction between ovarian cancer-associated fibroblasts (CAFs) and endothelial cells, demonstrating that CAFs contribute to resistance to anti-angiogenic drugs and aid in the development of drug resistance. These findings provide insight into potential strategies for overcoming CAF resistance and improving treatment outcomes in aggressive ovarian cancer.

BIOMEDICINES (2023)

Add to Collection

Article Oncology

Distinct Mechanisms of Mismatch-Repair Defi ciency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma

Ryan D. Chow et al.

Summary: This study found that patients with mutational MMRd endometrial cancer had higher response rates and longer survival after treatment with the PD-1 inhibitor pembrolizumab compared to those with epigenetic MMRd. However, mutation burden did not correlate with immune checkpoint blockade response. The study also revealed different modes of antitumor immunity between mutational and epigenetic MMRd cancers.

CANCER DISCOVERY (2023)

Add to Collection

Editorial Material Multidisciplinary Sciences

Precision immunotherapy

Aleksandar Obradovic

SCIENCE (2023)

Add to Collection

Article Engineering, Biomedical

Near-Infrared Responsive Membrane Nanovesicles Amplify Homologous Targeting Delivery of Anti-PD Immunotherapy against Metastatic Tumors

Ya-Nan Tan et al.

Summary: The study introduced a new cellular membrane nanovesicles platform for enhancing the efficacy of PD-1/PD-L1 blockade therapy against metastatic tumors. The platform targeted both primary tumors and metastases, promoting T cell infiltration and enhancing antigen presenting ability to inhibit tumor growth and metastasis.

ADVANCED HEALTHCARE MATERIALS (2022)

Add to Collection

Article Oncology

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study

Ana Oaknin et al.

Summary: Dostarlimab demonstrated durable antitumor activity in patients with endometrial cancer, with a manageable safety profile.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Mathematics, Interdisciplinary Applications

The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer

Benjamin Woelfl et al.

Summary: Evolutionary game theory can be applied to model cancer and improve treatment outcomes, offering hope for increased patient survival rates through evolutionary therapies. By predicting and steering the eco-evolutionary dynamics of cancer, it is possible to reduce drug toxicity and create more desirable states for patients.

DYNAMIC GAMES AND APPLICATIONS (2022)

Add to Collection

Article Oncology

Bete Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance

Pradip De et al.

Summary: This study focuses on the resistance of tumor cells to treatment, with a particular emphasis on the role of cancer-associated fibroblasts in promoting drug resistance in solid tumors.

CANCERS (2022)

Add to Collection

Review Oncology

Facts and Hopes in Immunotherapy of Endometrial Cancer

Juan A. Marin-Jimenez et al.

Summary: Immunotherapy has revolutionized the treatment of endometrial cancer by targeting different molecular subtypes and tumor microenvironment features.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Multidisciplinary Sciences

PD-L1-directed PlGF/VEGF blockade synergizes with chemotherapy by targeting CD141+ cancer-associated fibroblasts in pancreatic cancer

Duk Ki Kim et al.

Summary: Chemotherapy-induced fibrosis in PDAC is elucidated and a combinatorial therapeutic strategy for desmoplastic cancers is highlighted.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Physiology

DIVERSITY AND BIOLOGY OF CANCER-ASSOCIATED FIBROBLASTS

Giulia Biffi et al.

Summary: Efforts to develop anti-cancer therapies have mainly targeted the epithelial compartment, but recent studies have shown the significant influence of cancer-associated fibroblasts (CAFs) in tumor progression. CAFs not only promote cancer cell proliferation, therapy resistance, and immune exclusion, but may also restrain tumor progression in certain contexts. Research on CAFs has focused on their heterogeneity, plasticity, and functions across different cancer types and states, as well as advancements in therapeutic strategies targeting CAFs currently undergoing preclinical and clinical evaluation.

PHYSIOLOGICAL REVIEWS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives

Xiaoqi Mao et al.

Summary: CAFs, as a crucial component of TME, play significant roles in promoting tumor growth, invasion, and metastasis. The interaction between CAFs and tumor cells, as well as immune cells in TIME, is critical for tumor progression.

MOLECULAR CANCER (2021)

Add to Collection

Review Pathology

Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation

Elizabeth C. Paver et al.

Summary: Immunotherapy with checkpoint inhibitors, particularly PD-1/PD-L1 inhibitors, has shown efficacy in treating non-small cell lung cancer and melanoma. As clinical trials continue to expand the approved indications for these inhibitors, pathologists need to be familiar with the different PD-L1 testing methods and their impact on therapeutic decisions.

PATHOLOGY (2021)

Add to Collection

Article Oncology

PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance

Tao Zhang et al.

Summary: The study evaluated the expression and predictive value of PD-L1 in endometrial serous carcinoma (ESC), finding that PD-L1 positivity was associated with unfavorable outcomes in ESC and may serve as a potential therapeutic target for these tumors.

CANCER MANAGEMENT AND RESEARCH (2021)

Add to Collection

Review Oncology

Cancer-Associated Fibroblast Functions as a Road-Block in Cancer Therapy

Pradip De et al.

Summary: This review explores how cancer-associated fibroblasts interact with various cells in the tumor microenvironment to support the development of resistance to cancer therapy. Understanding the role of cancer-associated fibroblasts in treatment resistance is crucial for designing effective strategies to counteract drug resistance and improve treatment outcomes.

CANCERS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Cancer-Associated Fibroblasts in Conversation with Tumor Cells in Endometrial Cancers: A Partner in Crime

De Pradip et al.

Summary: The tumor microenvironment plays a critical role in tumor progression and clinical outcome, impacting tumor growth, progression, resistance to therapy, and therapeutic outcomes through interactions between tumor cells and the immune, vascular, and fibroblast components of TME.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Oncology

Exosomal lncRNA NEAT1 from cancer-associated fibroblasts facilitates endometrial cancer progression via miR-26a/b-5p-mediated STAT3/YKL-40 signaling pathway

Jiang-Tao Fan et al.

Summary: The study revealed that exosomal NEAT1 from cancer-associated fibroblasts contributes to the progression of endometrial cancer (EC) via modulation of the miR-26a/b-5p-mediated STAT3/YKL-40 pathway, indicating the therapeutic potential of exosomal NEAT1 for treating EC.

NEOPLASIA (2021)

Add to Collection

Article Pathology

PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells Differences Across Histologic and TCGA-based Molecular Subgroups

Annukka Pasanen et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)

Add to Collection

Meeting Abstract Oncology

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas

Shuang Zhang et al.

BMC CANCER (2020)

Add to Collection

Review Oncology

PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer

Cathalijne C. B. Post et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)

Add to Collection

Article Oncology

Extracellular vesicle encapsulated microRNA-320a inhibits endometrial cancer by suppression of the HIF1α/VEGFA axis

Na Zhang et al.

EXPERIMENTAL CELL RESEARCH (2020)

Add to Collection

Article Oncology

β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas

Margaret Rowe et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)

Add to Collection

Article Oncology

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Vicky Makker et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Pathology

Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas

Gozde Kir et al.

VIRCHOWS ARCHIV (2020)

Add to Collection

Article Immunology

Cancer-Associated Fibroblasts-Derived Exosomes Suppress Immune Cell Function in Breast Cancer via the miR-92/PD-L1 Pathway

Dongwei Dou et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Oncology

Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer A Nonrandomized Phase 1 Clinical Trial

Ana Oaknin et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Vicky Makker et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Ecology

Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer

Artem Kaznatcheev et al.

NATURE ECOLOGY & EVOLUTION (2019)

Add to Collection

Correction Medicine, Research & Experimental

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression (vol 128, pg 805, 2018)

Heng Lin et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

Add to Collection

Article Medicine, Research & Experimental

PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression

Haidong Tang et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

Add to Collection

Article Immunology

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

Vikram R. Juneja et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2017)

Add to Collection

Article Multidisciplinary Sciences

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice

Janet Lau et al.

NATURE COMMUNICATIONS (2017)

Add to Collection

Article Pathology

PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors

Emily A. Sloan et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)

Add to Collection

Article Oncology

A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage

Colette Dezutter-Dambuyant et al.

ONCOIMMUNOLOGY (2016)

Add to Collection

Article Multidisciplinary Sciences

Cancer-Associated Fibroblasts Promote Proliferation of Endometrial Cancer Cells

Kavita S. Subramaniam et al.

PLOS ONE (2013)

Add to Collection

© Peeref 2019-2024. All rights reserved.